-+ 0.00%
-+ 0.00%
-+ 0.00%

Longeveron Q2 net loss widens 22% to $6.07 million; revenue falls 10% to $287,000

PUBT·08/12/2026 20:04:56
Listen to the news
Longeveron Q2 net loss widens 22% to $6.07 million; revenue falls 10% to $287,000
  • Longeveron posted a net loss of USD 6.07 million, widening 22% year over year.
  • Revenue dipped 10% to USD 287,000, driven by no contract manufacturing revenue.
  • Operating loss widened to USD 6.17 million as operating expenses climbed 15% to USD 6.35 million.
  • Research and development spending rose 7% to USD 3.19 million on higher ELPIS II clinical trial costs.
  • Cash and cash equivalents totaled USD 10.1 million at June 30, 2026; cash runway expected into Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-346794), on August 12, 2026, and is solely responsible for the information contained therein.